Parkinson’s disease has long been associated with the gradual loss of dopamine-producing neurons, but the molecular events that push these cells toward irreversible damage remain a major target for research. A new study published in BMC Neuroscience investigates a delivery system designed to protect vulnerable neurons from two central features of Parkinsonian injury: oxidative stress and programmed cell death. The researchers tested alpha lipoic acid, a naturally occurring antioxidant, after packaging it inside folate-conjugated chitosan nanoparticles. In laboratory-grown neuronal cells exposed to 6-hydroxydopamine, a chemical commonly used to reproduce Parkinson’s-like damage in vitro, the formulation showed neuroprotective potential and helped counter biological changes associated with neuronal degeneration.
The study addresses a persistent problem in neuropharmacology: many potentially protective compounds are difficult to deliver efficiently to the nervous system. Alpha lipoic acid is capable of neutralizing reactive oxygen species and supporting the regeneration of other antioxidants, including glutathione. It also participates in mitochondrial metabolism, making it an attractive candidate for limiting the energy failure and oxidative injury observed in neurodegenerative disorders. Yet its therapeutic use can be constrained by chemical instability, limited cellular delivery and rapid distribution away from the intended target. The researchers therefore combined alpha lipoic acid with chitosan, a biodegradable polymer widely studied in drug-delivery systems, and added folate molecules to the nanoparticle surface to improve interaction with cells expressing folate receptors.
Nanoparticles are engineered structures typically measured in billionths of a metre, small enough to interact closely with cellular membranes and transport active compounds in a controlled form. Chitosan is particularly useful because it is biocompatible, can be chemically modified and carries a positive charge under many physiological conditions. That charge can promote adhesion to negatively charged cell membranes, potentially increasing the time available for uptake. Folate conjugation adds another layer of targeting logic. Folate receptors are involved in the transport of folic acid into cells and can be expressed at different levels depending on cell type and cellular state. In this study, the folate-bearing surface was intended to enhance nanoparticle–cell interactions and improve the delivery of alpha lipoic acid to the neuronal model.
To model Parkinson’s-related toxicity, the researchers used 6-hydroxydopamine, or 6-OHDA. This neurotoxin is taken up by catecholaminergic cells and undergoes oxidation, generating reactive oxygen species and other damaging intermediates. The resulting cascade can disrupt mitochondrial function, damage proteins and membranes, and activate apoptosis, the regulated form of cell death. Although a cell-culture model cannot reproduce the full complexity of the human brain, 6-OHDA exposure provides a controlled way to examine mechanisms relevant to dopaminergic neuron vulnerability. The investigators compared untreated cells, toxin-exposed cells and cells receiving alpha lipoic acid in nanoparticle form, allowing them to assess whether the delivery platform could reduce the cellular consequences of oxidative injury.
The findings indicate that 6-OHDA produced the expected pattern of cellular stress. Exposed cells showed reduced viability and evidence of oxidative imbalance, consistent with the toxin’s ability to overwhelm endogenous antioxidant defenses. The Parkinsonian insult was also associated with changes linked to apoptosis, suggesting that oxidative damage was not merely a temporary biochemical disturbance but part of a broader process leading toward cell loss. Such changes are important because dopaminergic neurons are especially sensitive to mitochondrial dysfunction and redox imbalance. Their high metabolic demand and extensive axonal architecture require substantial energy, leaving them vulnerable when reactive oxygen species accumulate faster than the cell can neutralize them.
Treatment with alpha lipoic acid-loaded folate-conjugated chitosan nanoparticles improved the condition of the damaged cells compared with the untreated 6-OHDA model. The nanoparticle formulation reduced indicators of oxidative stress and supported cell survival, while also moderating molecular signals associated with apoptosis. The protective effect is biologically plausible: alpha lipoic acid can directly participate in redox reactions, while nanoparticle encapsulation may preserve the compound and increase its intracellular availability. Rather than relying only on the antioxidant’s presence in the surrounding culture medium, the formulation is designed to bring the active molecule into closer contact with the cells and release it in a more sustained or locally effective manner.
The work also highlights the importance of examining apoptosis at the molecular level rather than measuring cell survival alone. Programmed cell death is controlled by a network of proteins that includes pro-apoptotic and anti-apoptotic regulators, mitochondrial signaling pathways and enzymes known as caspases. Oxidative stress can disturb this network by damaging mitochondrial membranes and promoting the release of factors that activate caspase-dependent cell death. By showing that the alpha lipoic acid nanoparticle treatment influenced markers connected with this pathway, the study suggests that the formulation may act downstream of the initial oxidative insult as well as helping to reduce the formation of damaging reactive molecules. This dual action could be valuable in diseases where oxidative injury and apoptosis reinforce one another.
The researchers’ approach is notable because it combines antioxidant therapy with a targeting strategy rather than treating alpha lipoic acid as a freely circulating compound. Folate conjugation may increase cellular uptake, while the chitosan carrier offers a structural framework for encapsulation and transport. However, the results should be interpreted as an early-stage demonstration rather than evidence of a treatment ready for patients. The experiments were conducted in vitro, using a simplified cellular environment that lacks the blood–brain barrier, immune interactions, vascular transport and the complex circuitry of the human substantia nigra. Nanoparticles that appear effective in cultured cells may behave differently in animals, where they must remain stable, reach the brain, avoid unwanted accumulation and release their cargo at a therapeutically useful concentration.
Further research will need to establish how the particles distribute through the nervous system, whether they can cross or bypass the blood–brain barrier, and how the body metabolizes both the chitosan carrier and its folate modification. Animal studies could determine whether the formulation protects dopamine neurons, preserves motor behavior and remains safe after repeated administration. Researchers will also need to compare the nanoparticles with unencapsulated alpha lipoic acid and with other delivery platforms to identify which component contributes most strongly to the observed benefit. Even so, the study provides a technically grounded proof of concept: by pairing a redox-active molecule with a biodegradable, folate-conjugated nanocarrier, it may be possible to target several interconnected mechanisms of Parkinson’s-related cellular damage at once. The strategy does not yet offer a cure, but it adds a promising direction to the search for interventions that protect neurons before degeneration becomes irreversible.
Subject of Research: Neuroprotective effects of alpha lipoic acid-loaded folate-conjugated chitosan nanoparticles in an in vitro Parkinson’s disease model.
Article Title: Evaluation of the neuroprotective effects of alpha lipoic acid-loaded folate-conjugated chitosan nanoparticles against 6-OHDA-induced apoptosis and oxidative stress in an in vitro Parkinson’s disease model
Article References: Published in BMC Neuroscience by Springer Nature.
Image Credits: AI Generated
DOI: 10.1186/s12868-025-00991-3
Keywords: Parkinson’s disease, alpha lipoic acid, folate-conjugated chitosan nanoparticles, 6-hydroxydopamine, oxidative stress, apoptosis, neuroprotection, drug delivery, dopaminergic neurons.
Tags: alpha-lipoic acid antioxidant therapy for Parkinson’s diseasecombating oxidative damage in neuronal cellsenhancing bioavailability of neuroprotective compoundsFolate-conjugated chitosan nanoparticles for targeted neuroprotectionin vitro Parkinson’s disease models with 6-hydroxydopaminemitochondrial support in neurodegenerationnanoparticle drug delivery for neurodegenerative disordersneuroneuron protection using nanocarriersoxidative stress mitigation in Parkinson’s modelstargeted delivery systems for Parkinson’s treatments
